Abstract

A systematic review of 10 studies has found that a single intravenous dose of ketamine reduced suicidal thoughts within a day in patients with a psychiatric disorder, with the effects of the dose lasting up to one week. The researchers stated that although these results should be considered preliminary, they suggest that ketamine appears promising as a rapid‐acting treatment for patients at acute risk of suicide. Results were published online Oct. 3 in the American Journal of Psychiatry.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call